FORM PTO-1390 (REV. 10-2003) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY 'S'DOCKET NUMBER MBM-104 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5 DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/CA03/00480 April 8, 2003 April 8, 2002 TITLE OF INVENTION Combinations of Antisense Oligonucleotides Directed Against Thymidylate Synthase MRNA and Uses Thereof APPLICANT(S) FOR DO/EO/US D. James Koropatnick, Mark D. Vincent Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau).  $\square$ has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Aplication under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) (unsigned). 10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. 🔽 A preliminary amendment. 14. 🔽 An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. 🔽 A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. A second copy of the published international application under 35 U.S.C. 154(d)(4). 18. 19.  $\square$ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. Other items or information: Copy of front page of the published application (PCT/CA03/00480) \*\* . . . .

DT04 Rec'd PCT/PTO 0 8 OCT 2004

U.S. APPLICATION TO G 15 10 10 10 10 10 10 10 10 10 10 10 10 10					ATTORNEY'S DOCKET NUMBER  MBM-104		
21. The follow	ring fees are submitted:			CAI	LCULATIONS F	PTO USE ONLY	
BASIC NATIONAL	L FEE (37 CFR 1.492 (a)					-	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO							
International prelin USPTO but Interna	ninary examination fee (3 ational Search Report pre						
International prelin but international se	minary examination fee (3 carch fee (37 CFR 1.445(a	7 CFR 1.482) not paid to a)(2)) paid to USPTO	o USPTO \$790.00				
but all claims did n	ninary examination fee (3 not satisfy provisions of P	\$750.00					
and all claims satist	ninary examination fee (3 fied provisions of PCT A R APPROPRIATE	article 33(1)-(4)	\$100.00	_	\$950.00		
	0 for furnishing the oath		<u> </u>	┼	<del></del>	<u> </u>	
months from the earl	liest claimed priority date	e (37 CFR 1.492(e)).		<u> </u>			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	***		
Total claims	15 - 20 =	0	x \$18.00	↓	\$0.00		
Independent claims MIII TIPLE DEPEN	$\boxed{3 - 3 = }$ DENT CLAIM(S) (if app	olicable)	x \$88.00 + \$300.00	}	\$0.00 \$0.00	<u> </u>	
MULTIF EL DEL EL		OF ABOVE CALCU	l	$\vdash$	\$950.00		
Applicant claim are reduced by	ns small entity status. See				\$475.00		
		S	UBTOTAL =	<u> </u>	\$475.00		
Processing fee of \$13 months from the earl	30.00 for furnishing the Eliest claimed priority date	English translation later the (37 CFR 1.492(f)).	han 20 30		\$0.00		
		TOTAL NATIO			\$475.00		
Fee for recording the accompanied by an a	e enclosed assignment (37 appropriate cover sheet (3	7 CFR 1.21(h)). The assi 37 CFR 3.28, 3.31). \$40.	ignment must be .00 per property +		\$0.00		
		TOTAL FEES E	NCLOSED =		\$475.00		
					ount to be refunded:	\$	
	_				charged:	\$	
<ul> <li>a. A check in the amount of \$ to cover the above fees is enclosed.</li> <li>b. Please charge my Deposit Account No 19-0065 in the amount of \$ 475.00 to cover the above fees. A duplicate copy of this sheet is enclosed.</li> <li>c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No 19-0065 . A duplicate copy of this sheet is enclosed.</li> </ul>							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.  CORRESPONDENCE ADDRESS:							
CUSTO	MER NUMBER		SIGNATU	RE	<del></del>	4	
		3, 2004 Frank C	). <u>Eise</u>	enschenk			
	23,557	DATE	NAME 45,332				
}			REGISTRA	ATION	NUMBER		



Patent Application Docket No. MBM-104

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

D. James Koropatnick, Mark D. Vincent

Docket No.

MBM-104

For

Combinations of Antisense Oligonucleotides Directed Against

Thymidylate Synthase MRNA and Uses Thereof

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

## CERTIFICATE OF MAILING BY EXPRESS MAIL (37 CFR §1.10)

Express Mail No.:	ER876766111US	Date of Deposit: October 8, 2004
_	ER876766111US	•

I hereby certify that the attached Transmittal Letter to the United States Designated/Elected Office (DO/EO/US), Preliminary Amendment, Application Data Sheet, cover page of published international application, and unexecuted Declaration (37 CFR §1.63) and Power of Attorney, with copies as required for authorization for use of Deposit Account No. 19-0065, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and are addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313.

Natalia Talero	March 1			
Name of person mailing paper	Signature			